TY - JOUR
T1 - Multiplexed rapid technologies for sexually transmitted infections
T2 - a systematic review
AU - Karellis, Angela
AU - Naeem, Faheel
AU - Nair, Suma
AU - Mallya, Sneha D.
AU - Routy, Jean Pierre
AU - Gahagan, Jacqueline
AU - Yansouni, Cédric P.
AU - Kim, John
AU - Pai, Nitika Pant
N1 - Funding Information:
We acknowledge the support of Geneviève Gore for her help in searching the literature and of Nandi Belinsky for her help during the manuscript submission process. This work was supported by grants from the Canadian Institute of Health Research (PJT 153149) and IC-IMPACTS. The agencies had no role in the writing of the manuscript or the decision to submit it for publication.
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/4
Y1 - 2022/4
N2 - Multiplexed technologies for sexually transmitted infections offer a convenient diagnostics option to screen, confirm, and treat multiple pathogens simultaneously. Due to scarce published real-world diagnostic performance data, we did a systematic review. Two reviewers searched major databases for data published between Jan 1, 2009, and April 20, 2020, and abstracted and analysed sensitivity and specificity data from 24 studies, which assessed 17 multiplex rapid nucleic acid amplification test platforms and seven multiplex immunochromatographic devices. Overall, these studies evaluated 19 sexually transmitted infections in 26 126 individuals. High sensitivity and specificity were shown for rapid nucleic acid amplification platform tests and immunochromatographic devices, with performance varying by pathogen, device, seropositivity, and subpopulation screened. As most devices yielded more than 95% sensitivity and specificity, immunochromatographic tests and rapid nucleic acid amplification test platforms can be advised for screening and confirmatory use. These highly accurate devices are appropriate for integrated, rapid screening initiatives for sexually transmitted infections to screen and treat many of these infections simultaneously, for antimicrobial stewardship, and for disease elimination programmes.
AB - Multiplexed technologies for sexually transmitted infections offer a convenient diagnostics option to screen, confirm, and treat multiple pathogens simultaneously. Due to scarce published real-world diagnostic performance data, we did a systematic review. Two reviewers searched major databases for data published between Jan 1, 2009, and April 20, 2020, and abstracted and analysed sensitivity and specificity data from 24 studies, which assessed 17 multiplex rapid nucleic acid amplification test platforms and seven multiplex immunochromatographic devices. Overall, these studies evaluated 19 sexually transmitted infections in 26 126 individuals. High sensitivity and specificity were shown for rapid nucleic acid amplification platform tests and immunochromatographic devices, with performance varying by pathogen, device, seropositivity, and subpopulation screened. As most devices yielded more than 95% sensitivity and specificity, immunochromatographic tests and rapid nucleic acid amplification test platforms can be advised for screening and confirmatory use. These highly accurate devices are appropriate for integrated, rapid screening initiatives for sexually transmitted infections to screen and treat many of these infections simultaneously, for antimicrobial stewardship, and for disease elimination programmes.
UR - http://www.scopus.com/inward/record.url?scp=85122935662&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122935662&partnerID=8YFLogxK
U2 - 10.1016/S2666-5247(21)00191-9
DO - 10.1016/S2666-5247(21)00191-9
M3 - Review article
AN - SCOPUS:85122935662
SN - 2666-5247
VL - 3
SP - e303-e315
JO - The Lancet Microbe
JF - The Lancet Microbe
IS - 4
ER -
